pipette
ESEspañol

Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study

S.-H. Chen, Y. H. Huang, Y.-H. Lee, S.-M. Yang, C.-J. Huang, Y.-K. Pang, Y.-Y. Chen, H.-M. Cheng

PreprintReal-world use

In the authors' words

Background Mineralocorticoid receptor antagonists (MRAs) are standard therapy for primary aldosteronism (PA). Serum potassium is measured in nearly every treated patient, but the long-term prognostic value of potassium attained early after initiation is undefined. Methods In the TriNetX Research Network, we identified adults with PA newly initiating spironolactone or eplerenone in 2000-2025, without prior adrenalectomy (n=4,169; 180-day landmark design). Achieved potassium (last value on days 14-180) was categorised as <4.0, 4.0-<4.5, 4.5-<5.0 and [&ge;]5.0 mmol/L, and its change from baseline in tertiles, using cause-specific Cox and Fine-Gray models. The primary outcome was a composite of myocardial infarction, stroke or death; incident heart failure was co-primary. Findings Over a median 3.0 years, 623 composite events occurred. Estimated risk was lowest at 4.5-<5.0 mmol/L (adjusted hazard ratio 0.65, 95% CI 0.52-0.83, versus <4.0 mmol/L), lower than the 4.0-<4.5 mmol/L band, and not different from [&ge;]5.0 mmol/L. A larger rise in potassium was associated with lower risk. A similar pattern was seen for incident heart failure (0.54, 0.36-0.80; 248 events). Potassium below the 3.6 mmol/L consensus threshold for hypokalaemia carried no significantly higher risk (1.22, 0.96-1.56). The change in potassium correlated weakly with the change in renin (rho = 0.15). Interpretation In MRA-treated PA, cardiovascular and heart-failure risk was lowest at an early achieved potassium of 4.5-<5.0 mmol/L, well above the 3.6 mmol/L accepted by consensus criteria as correction of hypokalaemia; correction alone may therefore be an insufficient treatment target. Whether titrating therapy towards this band improves outcomes requires prospective evaluation.

Main resultLimitation the authors admit

Appeared: Wednesday, November 18. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.15.26368152